Centocor T14 Study
- Date:
- 1994-1996
- Reference:
- SA/KET/A/1/4
- Part of:
- The Kennedy Trust for Rheumatology Research
- Archives and manuscripts
Collection contents
About this work
Description
Comprises records relating to the placebo controlled, investigator/patient blinded C0168T14 study "Phase II Multi-Centre Study of Chimeric Anti-TNF Monoclonal Antibody (cA2) in Adjunct to Methotrexate Treatment in Patients with Rheumatoid Arthritis."
The study led on from phase I and II of the cA2 studies and included a Centocor sponsored multicentre trial led by the Kennedy Institute of Rheumatology, with investigators Ravinder Maini, Marc Feldmann and Dr M. Elliott. The study aimed to assess the safety and effect of multiple infusions of cA2 alone or in combination with methotrexate (an immune suppressant commonly used in the treatment of Rheumatoid Arthritis). The study lasted c.28 weeks from the first infusion and involved 105 patients. Seven treatment groups were involved in the study across c.4 centres throughout Europen including London and the Charing Cross Hospital.
See SA/KET/A/2 for further Centocor research collaboration papers.